Sangamo to put ‘substantially all’ assets for sale in bankruptcy, lines up Lilly and Astellas as buyers
8 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Sangamo to put ‘substantially all’ assets for sale in bankruptcy, lines up Lilly and Astellas as buyers" is generating significant coverage in the Business category, with 8 articles from 8 distinct sources tracked by PULSE so far.
Outlets currently covering the story include marketscreener.com, FirstWord Pharma, The Business Journals and citybiz. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 45d ago.
Quick answers
Why is "Sangamo to put ‘substantially all’ assets for sale in bankruptcy, lines up Lilly" trending?
Because 8 independent news sources published 8 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (8)
- Sangamo Therapeutics, Inc. Filed for Bankruptcy marketscreener.com · 48d ago
- Lilly, Astellas bid on Sangamo's assets after bankruptcy filing FirstWord Pharma · 48d ago
- Sangamo Therapeutics files for bankruptcy as Lilly and Astellas split assets The Business Journals · 48d ago
- Sangamo Therapeutics Files for Chapter 11 Bankruptcy Protection citybiz · 48d ago
- Gene Therapy Developer Sangamo Hits Ch. 11 With Sale Plans Law360 · 48d ago
- Sangamo Therapeutics Sets Stalking Horse Sales: $50M to Eli Lilly, Up to $50M to Astellas TradingView · 48d ago
- UPDATE: Lilly, Astellas circle Sangamo assets as biotech files for bankruptcy BioSpace · 48d ago
- Sangamo to put ‘substantially all’ assets for sale in bankruptcy, lines up Lilly and Astellas as buyers Fierce Biotech · 48d ago
Topics
Related trends
The Race to Come Up With the Next Big Sleep Drug
Takeda's historic narcolepsy approval ignites a wave of new pharmaceutical development in the sleep drug market.
The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
CVS Health Launches Eli Lilly GLP-1 Partnership, Lifts Outlook as Profit Increases
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Eli Lilly Posts Higher Revenue on Continued GLP-1 Demand
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress
Eli Lilly’s 48% revenue surge eclipses a weak earnings report from The Trade Desk, reshaping market expectations for biotech and ad tech alike.